Sarepta nevertheless plans to push for full FDA approval of Vyondys 53 and Amondys 45 based on what it said are “encouraging ...

Two of Sarepta Therapeutics’ Duchenne muscular dystrophy (DMD) candidates have failed to reach their primary endpoint in a ...

Sarepta's Duchenne trial missed its main goal but showed trends favoring treatment; Q3 earnings topped estimates amid ...

Still, CEO Doug Ingram claimed removing the two drugs, Vyondys 53 and Amondys 45, from market would make “little sense” and ...

The ESSENCE trial was intended to prove the efficacy of Vyondys 53 (golodirsen) and Amondys 45 (casimersen), which received ...

Sarepta Therapeutics, Inc. (NASDAQ: SRPT) stock fell sharply Tuesday following disappointing results from a key clinical trial and ongoing concerns about its drug pipeline. However, "Pharma Bro" ...

Tuesday is shaping up to be another dark day in the stock market for US genetic medicines company Sarepta Therapeutics as key ...

Sarepta Therapeutics shares plunged 37% after two Duchenne muscular dystrophy drugs failed a key trial, raising regulatory ...

A long-running confirmatory trial of two of Sarepta Therapeutics’ Duchenne muscular dystrophy drugs has missed its main goal.

The S&P 500 Index ($SPX) (SPY) on Tuesday closed down -1.17%, the Dow Jones Industrials Index ($DOWI) (DIA) closed down -0.53 ...

Shares of Sarepta Therapeutics Inc. plunged in extended trading Monday after the biotechnology company disclosed ...

Sarepta Therapeutics' shares plunged nearly 40% in premarket trading on Tuesday as failure of two of its approved drugs for a ...